GPT and Nephropathy: In case of 10 patients adverse events occurred during DAA therapy and follow-up (Table S2), including portal vein thrombosis with liver failure, ascites, severe bacterial infections, vasculitis, nephropathy, monoclonal gammopathy, lymphomas and rapidly elevating ALT after treatment (Table S2).